Study Reveals Potential Tardive Dyskinesia Biomarkers
An analysis of blood serum has identified differences between patients with tardive dyskinesia (TD) and people who have not developed the movement disorder. Researchers presented their findings at the 30th European College of Neuropsychopharmacology Congress in Paris last month.
“The biological processes that might play a role in the development of tardive dyskinesia are not confined to the human brain per se,” researchers wrote in a poster abstract. “Hormonal and immune systems are also involved, which may be related to these systems being closely interrelated.”
Researchers from Russia and the Netherlands analyzed blood serum from 180 patients who were on long-term antipsychotic treatment for schizophrenia. Among the study participants, 71 had TD and 109 did not.
Compared to patients without TD, patients with the movement disorder had significantly decrease in brain-derived neurotrophic factor and an increase in interleukin 6, researchers reported. A statistical trend of increased S100β was also identified in patients with TD.
“These parameters may provide information about risk factors of the movement disorder,” researchers concluded. “Identifying markers that can be used as diagnostics or predictors of treatment response in people with tardive dyskinesia will be an important step towards being able to provide personalized treatment.”
Boiko AS, Kornetova EG, Ivanova SA, Loonen AJM. Potential biomarkers of tardive dyskinesia: a multiplex analysis of blood serum. Poster presented at the 30th European College of Neuropsychopharmacology Congress; September 2-5, 2017; Paris, France.